Successful desensitization to imiglucerase of an adult patient diagnosed with type i gaucher disease

International Archives of Allergy and Immunology

Volumn 160, Issue 2, 2013, Pages 215-217

  Erdoǧdu, Derya ^a   Gelincik, Asli ^a   Canbaz, Bülent ^a   Colakoǧlu, Bahattin ^a   Büyüköztürk, Suna ^a   Tanakol, Refik ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Anaphylaxis; Desensitization; Gaucher disease; Imiglucerase

Indexed keywords

IMIGLUCERASE; ACETYLSALICYLIC ACID; METHYLPREDNISOLONE; PHENIRAMINE;

ADULT; ANAPHYLAXIS; ARTICLE; CASE REPORT; DESENSITIZATION; DIZZINESS; DRUG WITHDRAWAL; ENZYME REPLACEMENT; FAINTNESS; FEMALE; GAUCHER DISEASE; HEADACHE; HUMAN; HYPOTENSION; INTENSIVE CARE; PRICK TEST; PRIORITY JOURNAL; PRURITUS; ANEMIA; DILUTION; FLUSHING; INTRACUTANEOUS TEST; OUTPATIENT DEPARTMENT; SKIN TEST; THROMBOCYTOPENIA;

ADULT; ANAPHYLAXIS; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; ENZYME REPLACEMENT THERAPY; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS;

EID: 84866635521     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000339754     Document Type: Article

References (12)

1. Goldin E, Zheng W, Motabar O, Southall N, Hyuk Choi JH, Marugan J, Austin CP, Sidransky E: High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase. PLoS One 2012; 7: E29861.
2. Rhouma FM, Kallel F, Kefi R, Cherif W, Nagara M, Azaiez H, Jedidi I, Elloumi M, Abdelhak S, Mseddi S: Adult Gaucher disease in Southern Tunisia: Report of three cases. Diagn Pathol 2012; 7: 4.
3. Starzyk K, Richards S, Yee J, Smith SE, Kingma W: The long-Term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metabol 2007; 90: 157-163.
4. Aviner S, Levy Y, Yaniv I, Cohen IJ: Anaphylactoid reaction to imiglucerase, but not to alglucerase, in a type I Gaucher patient. Blood Cells Mol Dis 1999; 25: 92-94.
5. Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Muñoz ET, Solorio-Meza SE, Amato D, Duran G, Giona F, Heitner R, Rosenbaum H, Giraldo P, Mehta A, Park G, Phillips M, Elstein D, Altarescu G, Szleifer M, Hashmueli S, Aviezer D: Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011; 118: 5767-5773.
6. Morris JL: Velaglucerase alfa for the management of type 1 Gaucher disease. Clin Ther 2012; 34: 259-271.
7. Machaczka M, Hast R, Dahlman I, Lerner R, Klimkowska M, Engvall M, Hagglund H: Substrate reduction therapy with miglustat for type 1 Gaucher disease: A retrospective analysis from a single institution. Upsala J Med Sci 2012; 117: 28-34.
8. Lukina E, Watman N, Arreguin EA, Banikazemi M, Iastrebner MDM, Rosenbaum H, Phillips M, Pastores GM, Rosenthal DI, Kaper M, Singh T, Puga AC, Bonate PL, Peterschmitt MJ: A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 2010; 116: 893-899.
9. Elstein D, Altarescu G, Maayan H, Phillips M, Abrahamov A, Hadas-Halpern I, Tiomkin M, Zimran A: Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-Term imiglucerase therapy: Early Access Program results from Jerusalem. Blood Cells Mol Dis 2012; 48: 45-50.
10. Peroni DG, Pescollderungg L, Piacentini GL, Cassar W, Boner AL: Effective desensitization to imiglucerase in a patient with type I Gaucher disease. J Pediatr 2009; 155: 940-941.
11. Thong BY: Clinical applications of drug desensitization in the Asia-Pacific region. Asia Pac Allergy 2011; 1: 2-11.
12. Kilic M, Dogan Y, Taskin E, Sen Y, Kalpaklioglu AF: Desensitization protocol administered successfully with interferon-2 a in a child with chronic hepatitis B infection. J Invest Allergol Clin Immunol 2010; 20: 446-453.